An investigation was announced on behalf investors in NASDAQ:PRTO shares over potential securities laws violations by Proteon Therapeutics Inc and certain of its directors and officers.
Investors who purchased shares of Proteon Therapeutics Inc (NASDAQ:PRTO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Proteon Therapeutics Inc (NASDAQ:PRTO) concerning whether certain statements by Proteon Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On December 13, 2016, Proteon Therapeutics Inc announced that vonapanitase did not meet its primary endpoint in its first Phase 3 PATENCY-1 clinical trial. Shares of Proteon Therapeutics Inc NASDAQ:PRTO) declined from $10.58 per share on December 8, 2016 to as low as $1.51 per share on March 21, 2017.
Those who purchased NASDAQ:PRTO shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com